Jayesh Desai

Jayesh Desai at Peter MacCallum Cancer Centre has contributed to clinical investigation of EZH2 inhibitors and the synthetic lethal relationship between ARID1A loss and EZH2 dependence in cancer. His early-phase trial work includes studies of tazemetostat and other EZH2 inhibitors in SWI/SNF-mutant cancers, exploiting ARID1A/EZH2 synthetic lethality discovered in ovarian clear cell and other ARID1A-deficient tumors. His research spans epithelial cancers and sarcomas with chromatin remodeling gene defects. He contributes to defining patient selection biomarkers for epigenetic synthetic lethal approaches.